Your Money >>>

Dendreon presented strong data on Provenge trials at the American Urological Association, including trial results focusing on Provenge in African Americans.

After a disappointing end to 2011 regarding its lead drug, Exelixis is looking to bounce back with new data in its ASCO abstracts.

When doctors are pitched asset protection planning by a local or national guru, what they are pitched is not even half of what needs to be done to have a complete asset protection plan.

The run up of stocks before the American Society of Clinical Oncology conference has begun if Array BioPharma’s stock jump is any indication.

While you probably don’t have an antique that’s “a national treasure” lying around, you may have some unusually valuable possessions that call for special insurance coverage.

Many investors don't realize they're only doing 30% of the “work” necessary to get the most out of their investments. They’re doing this by simply ignoring companies that operate outside of the United States.

Finally, satisfaction with investment firms is nearly equal to pre-recession levels; however, three key areas are lagging.

After losing the patent on antipsychotic Zyprexa in 2011, analysts expected Eli Lilly to have a weak first quarter, but it looks like the company has some upside for 2013.

While the loss of assets to a soon-to-be-ex can never be avoided, some of the financial pain of a split can be minimized — with proper advance planning.

Brokers are taking the time to reach out to their clients more these days. They’re using the technology that’s available to them to keep investors confident in investing.